Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

ConclusionThe combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research